ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NVAX Novavax Inc

4.65
-0.02 (-0.43%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novavax Inc NASDAQ:NVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.02 -0.43% 4.65 4.69 4.72 4.78 4.60 4.69 3,689,738 00:58:28

Novavax to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on August 8, 2017

01/08/2017 9:05pm

GlobeNewswire


GAITHERSBURG, Md., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter financial and operating results following the close of U.S. financial markets on Tuesday, August 8, 2017.

Conference call details are as follows:

Date:Tuesday, August 8, 2017
Time:4:30 p.m. U.S. Eastern Time (ET)
Dial-in number:(877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode:15614203
Webcast:www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates:Starts at 7:30 p.m. ET, August 8, 2017 until 7:30 pm ET, August 15, 2017
Dial-in number:(855) 859-2056 (Domestic) or (404) 537-3406 (International) 
Passcode:15614203 
Webcast:www.novavax.com, "Investors"/ "Events", until November 8, 2017

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact:         

Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor Relations
ir@novavax.com  
240-268-2000
               
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com 
212-845-4271  




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

1 Year Novavax Chart

1 Year Novavax Chart

1 Month Novavax Chart

1 Month Novavax Chart

Your Recent History

Delayed Upgrade Clock